$PCRX.V

PharmaCorp Rx Initiated at Outperform, $0.70 Price Target at Raymond James

PharmaCorp Rx Inc. (PCRX.V) was rated Outperform with a $0.70 price target in new coverage at Raymond James.Analyst Fred Gatali initiated coverage of the Saskatoon, Saskatchewan-based retail pharmacy acquisition and ownership company.Gatali said PharmaCorp has access to more than 1,100 independently-owned pharmacies and holds a right-of-first-refusal to acquire them."In addition, the company has a retail collaboration agreement with McKesson Canada's 2,000+ independent pharmacies as a partner in supporting owners who are considering ownership changes or need longer-term capital solutions," the analyst said in a note to clients."Notable is what we consider to be a flexible exit structure PharmaCorp provides to sellers, which we view as an important element of its acquisition strategy, which may allow an owner to monetize their pharmacy, but remain involved in the business to preserve customer relationships, support staff continuity, and maintain a role in the local community."

Earnings Flash (PCRX.V) PharmaCorp Reports Q1 Revenue $7.2M, Up 79.4% YoY

PharmaCorp Rx up 10% as Announces Pharmacy Acquisition

PharmaCorp Rx (PCRX.V), up 10.4% on last look, is acquiring a PharmaChoice Canada-bannered pharmacy in Morrisburg, Ontario, for $8.2 million, the company said on Monday.PharmaCorp had executed letters of intent earlier this year regarding four additional pharmacy acquisitions. The Morrisburg pharmacy is the first conversion of the LOIs into a share purchase agreement.The acquisition, which is expected to close within 60 days, will increase PharmaCorp's store count to 15, including the eight PharmaChoice-bannered pharmacies in Eastern Canada, announced last month.PharmaCorp shares were last seen up $0.05 to $0.53 on the TSX Venture Exchange.Price: $0.53, Change: $+0.05, Percent Change: +10.42%

PharmaCorp Rx Acquires Eight Pharmacies For $24.2 Million

PharmaCorp Rx (PCRX.V) on Thursday said it agreed to acquire eight PharmaChoice Canada-bannered pharmacies in Eastern Canada for $24.2 million.The acquisitions, which will be financed with existing cash on hand, expands PharmaCorp's geographical footprint and operating scale, a statement said. All locations will continue to be operated by their existing managing pharmacists.The acquisitions are expected to close within 60 days.PharmaCorp also signed non-binding letters to acquire four morel pharmacies, which, if completed, are expected to close over the next two quarters."The acquisitions reflect the continued execution of our acquisition strategy and the strength of our sourcing network," said executive chair Alan Simpson. "The clustering of these locations within a key urban market, combined with the continuity of experienced managing pharmacists, positions us to integrate efficiently while maintaining strong local relationships and operating performance. We are seeing an increasing number of acquisition opportunities where we are engaged early in the process, allowing us to selectively pursue acquisitions that align with our disciplined approach to valuation, integration, and long-term value creation."PharmaCorp shares closed up $0.07 to $0.50 on the TSX Venture Exchange.